Rosenblum Silverman Sutton S F Decreased Gilead Sciences (GILD) Position By $606,056; Trover Solutions Has 1.08 Sentiment

June 20, 2017 - By Darrin Black

Trovagene, Inc. is a molecular diagnostic company. The company has market cap of $27.17 million. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. It currently has negative earnings. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Rosenblum Silverman Sutton S F Inc decreased Gilead Sciences Inc. (GILD) stake by 13.11% reported in 2016Q4 SEC filing. Rosenblum Silverman Sutton S F Inc sold 8,536 shares as Gilead Sciences Inc. (GILD)’s stock declined 8.05%. The Rosenblum Silverman Sutton S F Inc holds 56,586 shares with $4.05 million value, down from 65,122 last quarter. Gilead Sciences Inc. now has $86.82B valuation. The stock rose 1.40% or $0.9 reaching $65.72. About 8.19M shares traded or 10.08% up from the average. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since June 20, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Investors sentiment decreased to 0.7 in Q4 2016. Its down 0.23, from 0.93 in 2016Q3. It dropped, as 106 investors sold GILD shares while 656 reduced holdings. 111 funds opened positions while 421 raised stakes. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. Secor Cap Advisors Limited Partnership holds 35,197 shares. Cetera Advisor Ntwk Limited owns 36,099 shares. Century Cos owns 0.5% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 6.46 million shares. Glenview National Bank Tru Dept accumulated 27,409 shares or 1.07% of the stock. Korea holds 0.55% or 1.59 million shares in its portfolio. Gabelli Funds reported 0.03% in Gilead Sciences, Inc. (NASDAQ:GILD). Asset Management accumulated 122,500 shares. Ashmore Gp Plc invested in 0.05% or 1,000 shares. Domini Impact Invs Lc, a New York-based fund reported 4,906 shares. The Washington-based Merriman Wealth Mgmt Limited Company has invested 0.52% in Gilead Sciences, Inc. (NASDAQ:GILD). Homrich And Berg invested in 0.02% or 3,537 shares. Reynders Mcveigh Cap Mngmt Ltd holds 0.87% or 85,087 shares in its portfolio. Carnegie Capital Asset Mgmt Ltd Liability Corp stated it has 36,874 shares or 0.37% of all its holdings. State Of New Jersey Common Pension Fund D holds 2.22M shares. Daiwa Sb Investments, a Japan-based fund reported 130 shares.

Among 27 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 9 Hold. Therefore 67% are positive. Gilead Sciences had 65 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Wednesday, July 29 by Oppenheimer. As per Monday, September 21, the company rating was maintained by Cowen & Co. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Friday, April 29 by UBS. The rating was maintained by Credit Suisse on Wednesday, September 14 with “Outperform”. The firm has “Hold” rating by Jefferies given on Wednesday, August 31. The rating was maintained by Credit Suisse on Wednesday, March 23 with “Outperform”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by Leerink Swann on Friday, February 5. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by BMO Capital Markets on Wednesday, November 2. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by Credit Suisse on Wednesday, January 20. Citigroup initiated the shares of GILD in report on Thursday, February 25 with “Buy” rating.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 24. They expect $2.13 EPS, down 29.70% or $0.90 from last year’s $3.03 per share. GILD’s profit will be $2.81 billion for 7.71 P/E if the $2.13 EPS becomes a reality. After $2.20 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -3.18% negative EPS growth.

Since January 3, 2017, it had 0 buys, and 11 sales for $33.68 million activity. WILSON GAYLE E had sold 20,365 shares worth $1.41M on Thursday, February 23. Alton Gregg H sold 5,000 shares worth $325,114. Shares for $5.32 million were sold by MARTIN JOHN C. Cogan John Francis sold $668,667 worth of stock or 9,943 shares.

Elkhorn Partners Limited Partnership holds 0.15% of its portfolio in TrovaGene Inc for 118,500 shares. Messner & Smith Theme Value Investment Management Ltd Ca owns 34,075 shares or 0.12% of their US portfolio. Moreover, Princeton Capital Management Inc has 0.06% invested in the company for 40,170 shares. The Minnesota-based Windsor Financial Group Llc has invested 0.06% in the stock. Two Sigma Securities Llc, a New York-based fund reported 33,252 shares.

About 204,837 shares traded. TrovaGene Inc (TROV) has declined 83.95% since June 20, 2016 and is downtrending. It has underperformed by 100.65% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: